Alternating hemiplegia of childhood – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:33:28 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Alternating hemiplegia of childhood – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Oxygen and Nitrous Oxide for Treating Dystonic and Plegic Attacks in Children with Alternating Hemiplegia https://clinicaltrials.eu/trial/study-on-oxygen-and-nitrous-oxide-for-treating-dystonic-and-plegic-attacks-in-children-with-alternating-hemiplegia/ Wed, 29 Apr 2026 14:30:39 +0000 https://clinicaltrials.eu/trial/study-on-oxygen-and-nitrous-oxide-for-treating-dystonic-and-plegic-attacks-in-children-with-alternating-hemiplegia/ This clinical trial is focused on studying a rare neurological disorder called Alternating Hemiplegia of Childhood (AHC). AHC is a condition that causes sudden episodes of paralysis or muscle stiffness, known as dystonic or plegic attacks. The study aims to evaluate the effectiveness of a treatment using high-flow oxygen therapy to manage these acute attacks. The treatment involves inhaling a mixture of nitrous oxide and oxygen, commonly known as laughing gas, through a facial mask. This therapy will be compared to a placebo to determine its impact on stopping motor attacks.

Participants in the study will receive the treatment over a period of five weeks. During this time, the main focus will be on observing whether the high-flow oxygen therapy can stop the motor attacks within 30 minutes of their onset. The study does not involve any long-term treatment changes, ensuring that participants’ existing treatments remain stable throughout the trial.

The goal of this research is to provide a better understanding of how high-flow oxygen therapy can be used as an immediate treatment for the sudden and distressing symptoms of AHC. By comparing the effects of the therapy against a placebo, researchers hope to gather valuable information that could lead to improved management of this challenging condition.

]]>